Technology | December 20, 2013

Scanner is designed for demanding clinical and research challenges

Siemens Receives FDA Clearance for Magnetom Prisma 3T MRI System

Siemens Healthcare has announced that the Food and Drug Administration (FDA) has cleared the Magnetom Prisma, a 3 Tesla (3T) magnetic resonance imaging (MRI) scanner capable of extraordinarily high spatial and temporal resolution to achieve outstanding image quality, particularly in highly demanding applications.

“Siemens is proud to add the Magnetom Prisma 3T scanner to our portfolio of world-class MRI systems,” said Gregory Sorensen, M.D., CEO of Siemens Healthcare North America. “With applications that display functional information and enable the visualization of details in the smallest anatomical structures, the MAGNETOM Prisma enables researchers to explore bold new territories and address their specific research needs.”

The Magnetom Prisma features XR Gradients, which combine 80 milliTesla per meter (mT/m) with a 200T-per-meter-per-second (T/m/s) slew rate to offer a configuration unavailable in any other commercial whole-body system. Complementing the extraordinary power of the Magnetom Prisma’s XR Gradients is the system’s exceptionally robust design. Precision is maintained throughout long, demanding applications such as functional MRI (fMRI). The power and endurance of the Magnetom Prisma’s XR Gradients fuel the system’s first-to-market Diffusion Spectrum Imaging (DSI) acquisition that enables the user to potentially resolve fine anatomical details of the brain such as crossing white-matter fibers.

Image quality is further enhanced by the Magnetom Prisma’s benchmark homogeneity and advanced shimming solutions that allow for finer, more effective compensation of patient-induced field disturbances. Together, these features provide the user with an outstanding basis for cardiac and body imaging, as well as applications such as spectroscopy.

The Magnetom Prisma possesses Siemens’ Dot (Day optimizing throughput) engines that enable exceptional consistency, which is crucial both in research applications and clinical work. The Dot engine brings automation and reproducibility to investigations across subjects, time points, and institutions, raising the integrity of longitudinal studies and multi-site research projects.

Siemens will offer onsite upgrades to the MAGNETOM Prisma to customers who have already installed the MAGNETOM Trio, a 3T MRI system with Tim (Total imaging matrix) technology.

For more information: www.siemens.com/healthcare


Related Content

News | Radiology Business

March 12, 2026 — DelveInsight's has released its latest Diagnostic Imaging Equipment Market Insights report. The in ...

Time March 13, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | HIMSS

March 3, 2026 — MedDream will present its cloud-native, AI-ready universal DICOM viewer in the Amazon Web Services (AWS) ...

Time March 03, 2026
arrow
News

Feb. 26, 2026 — GE HealthCare and UCSF Health have announced a 10-year Care Alliance collaboration focused on ...

Time March 02, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | Contrast Media

Feb. 23, 2026 — Bracco, a global leader in diagnostic imaging, recently announced that the U.S. Food and Drug ...

Time February 24, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
Subscribe Now